TRIlogy-5 — JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma

Trial information

Medical condition

Relapsed or refractory multiple myeloma after 1–3 prior lines of therapy, including an anti-CD38 antibody and lenalidomide

Trial phase

Phase 3

Sponsor

Janssen Research & Development, LLC

Start date

31/05/2026

End date

08/12/2032

Main objective

Compare the efficacy and safety of JNJ-79635322 with teclistamab in participants with relapsed or refractory multiple myeloma.

Locations and Contact points